**Chai Discovery Secures $130M Series B Funding at $1.3B Valuation**
Biotech firm Chai Discovery, known for its innovative approach to drug discovery and backed by OpenAI, has announced a successful Series B funding round, raising a substantial $130 million. This significant investment now places the company’s valuation at an impressive $1.3 billion, underscoring investor confidence in its technological prowess and future potential.
The capital infusion is expected to accelerate Chai Discovery’s research and development efforts, pushing forward its pipeline of therapeutic candidates and expanding its computational biology platforms. The strategic support from OpenAI highlights a growing trend of cross-industry collaboration, where artificial intelligence is leveraged to revolutionize traditionally complex and time-consuming scientific fields like biotechnology and drug development. This latest funding round positions Chai Discovery as a significant player in the evolving landscape of AI-driven healthcare innovation.